Yael Barer

Ms. Yael Barer

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 August 2020 in JMIR Public Health and Surveillance
Verified
Journal Article
Open access
CYChen Yanover
Chen Yanover
BMBarak Mizrahi
Barak Mizrahi
NKNir Kalkstein
Nir Kalkstein
KMKarni Marcus
Karni Marcus
PAPinchas Akiva
Pinchas Akiva
Gabriel ChodickGabriel Chodick
Gabriel Chodick
Background: Reliably identifying patients at increased risk for coronavirus disease (COVID-19) complications could guide clinical decisions, public health policies, and preparedness efforts. Multiple studies have attempted to characterize at-risk patients, using various data sources and methodologies. Most of these studies, however, explored condition-specific patient cohorts (eg, hospitalized patients) or had limited access to patients’ medical history, thus, investigating related questions and, potentially, obtaining biased results. Objective: This study aimed to identify factors associated with COVID-19 complications from the complete medical records of a nationally representative cohort of patients, with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Methods: We studied a cohort of all SARS-CoV-2–positive individuals, confirmed by polymerase chain reaction testing of either nasopharyngeal or saliva samples, in a nationwide health organization (covering 2.3 million individuals) and identified those who suffered from serious complications (ie, experienced moderate or severe symptoms of COVID-19, admitted to the intensive care unit, or died). We then compared the prevalence of pre-existing conditions, extracted from electronic health records, between complicated and noncomplicated COVID-19 patient cohorts to identify the conditions that significantly increase the risk of disease complications, in various age and sex strata. Results: Of the 4353 SARS-CoV-2–positive individuals, 173 (4%) patients suffered from COVID-19 complications (all age ≥18 years). Our analysis suggests that cardiovascular and kidney diseases, obesity, and hypertension are significant risk factors for COVID-19 complications. It also indicates that depression (eg, males ≥65 years: odds ratio [OR] 2.94, 95% CI 1.55-5.58; P=.01) as well as cognitive and neurological disorders (eg, individuals ≥65 years old: OR 2.65, 95% CI 1.69-4.17; P<.001) are significant risk factors. Smoking and presence of respiratory diseases do not significantly increase the risk of complications. Conclusions: Our analysis agrees with previous studies on multiple risk factors, including hypertension and obesity. It also finds depression as well as cognitive and neurological disorders, but not smoking and respiratory diseases, to be significantly associated with COVID-19 complications. Adjusting existing risk definitions following these observations may improve their accuracy and impact the global pandemic containment and recovery efforts.

24 August 2022 in Brain Sciences
Verified
Journal Article
Open access
PDF file
YBYael Barer
Yael Barer
Gabriel ChodickGabriel Chodick
Gabriel Chodick
RCRaanan Cohen
Raanan Cohen
MGMeital Grabarnik-John
Meital Grabarnik-John
XYXiaolan Ye
Xiaolan Ye
TGTanya Gurevich
Tanya Gurevich
Progressive supranuclear palsy (PSP) is a rare and fatal neurodegenerative movement disorder and no disease modifying therapy (DMT) is currently available. This study aims to assess the epidemiology of PSP in Israel and to describe its clinical features. This retrospective analysis identified patients with PSP between 2000 and 2018 over the age of 40 years at first diagnosis (index date). We identified 209 patients with ≥1 diagnosis of PSP. Of those, 88 patients satisfied the inclusion criteria with a mean age at diagnosis of 72 years (SD = 8) and 53% were female. The 2018 prevalence and incidence rates were 5.3 and 1 per 100,000 persons, respectively. Median survival time was 4.9 years (95% CI 3.6–6.1) and median time from initial symptom to diagnosis was 4.2 years. The most common misdiagnoses were Parkinson’s disease, cognitive disorder and depression. The present study demonstrates that the clinic-epidemiological features of PSP in Israel are similar to PSP worldwide. In light of PSP’s rarity, investigation of PSP cohorts in different countries may create a proper platform for upcoming DMT trials.

1 December 2019 in Cancer Epidemiology
Verified
Journal Article
Closed access
DGDaniella Gilboa
Daniella Gilboa
GKGideon Koren
Gideon Koren
YBYael Barer
Yael Barer
RKRachel Katz
Rachel Katz
RRRam Rotem
Ram Rotem
VSVarda Shalev
Varda Shalev

4 August 2022 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
YBYael Barer
Yael Barer
GCGabriel Chodick
Gabriel Chodick
NCNurit Glaser Chodick
Nurit Glaser Chodick
TGTanya Gurevich
Tanya Gurevich
Parkinson disease (PD) is the second most common neurodegenerative disease, after Alzheimer disease, with a lifetime prevalence of approximately 1.5%.1,2 PD is manifested by the loss of dopamine-producing neurons in the substantia nigra, resulting in various motor and nonmotor symptoms.3 PD risk is associated with multiple environmental, behavioral, and biological4 risk factors.

13 November 2018 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Closed access
PDF file
YBYael Barer
Yael Barer
OCOhad Cohen
Ohad Cohen
TCTali Cukierman‐Yaffe
Tali Cukierman‐Yaffe

29 April 2022 in Movement Disorders Clinical Practice
Verified
Journal Article
Closed access
YBYael Barer
Yael Barer
TGTanya Gurevich
Tanya Gurevich
GCGabriel Chodick
Gabriel Chodick
NGNir Giladi
Nir Giladi
RGRuth Gross
Ruth Gross
ATAvner Thaler
Avner Thaler